Search

Olmutinib

Olmutinib recieved breakthrough therapy designation in the United States in December 2015 and was approved for use in Korea in May 2016. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.

Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen

grown in another culture. … Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria

EGS21

GC is a glycolipid that has been shown by Enzo scientists and collaborators to act as an anti-inflammatory agent in animal model systems, and therefore is being evaluated as an important candidate … drug in the treatment of various immune mediated diseases, such as Crohn's disease, hepatitis, non-alcoholic steatohepatitis (NASH) or fatty liver and HIV.

Atractylodes japonica root oil

It is present in some cosmetic products such as whitening creams as an active ingredient and lubricant for skin irritation.

DNB-001

In preclinical animal models, DNB-001 has demonstrated potent IOP- lowering effects as well as neuroprotective effects on the optic nerve. … DNB-001 is a first-in-class oral therapy with dual mechanism of action, which is initially being developed for the treatment of glaucoma.

EDP1815

EDP1815, was investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions

Mitemcinal

Mitemcinal (GM-611) is a novel erythromycin-derived prokinetic agent that acts as an agonist at the motilin receptor.

Dimethylcurcumin

Dimethylcurcumin is a synthetic chemical compound that is loosely based on a compound found in curcumin. It is a novel anti-androgen that enhances androgen receptor degradation.

Cadralazine

Butylated hydroxytoluene